Table 1.
Characteristic | Total (n = 151) | Chemotherapy only (control) (n = 77) | Immunotherapy (n = 74) | P |
---|---|---|---|---|
Sex, male/female | 101/50 | 58/19 | 43/31 | 0.037 |
Age (year), median ± SE | 57.0 ± 1.2 | 56 ± 1.5 | 58 ± 2.1 | 0.692 |
ECOG performance status | ||||
0/1 | 136 | 69 | 67 | 0.915 |
2 | 15 | 8 | 7 | |
Surgical procedure | ||||
Partial gastrectomy | 82 | 39 | 40 | 0.745 |
Total gastrectomy | 69 | 38 | 34 | |
Location of tumor | ||||
Upper | 39 | 18 | 21 | 0.772 |
Middle | 41 | 22 | 19 | |
Lower | 71 | 37 | 34 | |
Pathological type of tumor | ||||
Intestinal type | 98 | 51 | 47 | 0.598 |
Diffuse | 42 | 22 | 20 | |
Mixed type | 11 | 4 | 7 | |
Histologic differentiation | ||||
Well differentiated | 41 | 23 | 18 | 0.644 |
Poorly differentiated | 78 | 37 | 41 | |
Signet-ring cell | 32 | 17 | 15 | |
UICC stage | ||||
IIIA | 46 | 24 | 22 | 0.837 |
IIIB | 72 | 35 | 37 | |
VI | 33 | 18 | 15 | |
Chemotherapy regimen | ||||
Cisplatin | 28 | 18 | 10 | 0.101 |
Oxaliplatin | 79 | 34 | 45 | |
Docetaxel | 44 | 25 | 19 |
SE indicates standard error; ECOG Eastern Cooperative Oncology Group, UICC International Union Against Cancer